Market Introduction
Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and bioprocessing (i.e., biopharmaceutical manufacturing). Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat disease.
Thus, the growing approvals for cell therapies is expected to create a significant demand for cell therapy bioprocessing in the coming years, which is further anticipated to drive the cell therapy bioprocessing market.
As expected, many companies, including hardware and service providers, are increasing their pandemic-related R&D and manufacturing. Suppliers are bracing for increased business as companies and governments rush to develop, test, and deploy pandemic-related vaccines, therapeutics, and diagnostics. There has also been a demand for increased short-term supply stockpiling. However, in long run the demand for the cell therapy bioprocessing is expected to increase owing to supportive government initiatives. For instance, UK government has allotted 100 million Euros funds to the Cell and Gene Therapy Catapult Manufacturing Innovation Centre to expedite the production of a vaccine for COVID-19 in the UK. Moreover, Stempeutics Research has filed application seeking European Commission Funding to develop cell therapy for COVID 19. The company has also entered into partnership with global consortium of cell therapy companies to gather funding for cell therapy research from European commission. Hence, Europe Cell therapy bioprocessing market is likely to show significant growth prospects during this pandemic and forecasted year.
Market Overview and Dynamics
The Cell therapy bioprocessing market in Europe is expected to grow from US$ 3,627.3 million in 2021 to US$ 8,652.1 million by 2028; it is estimated to grow at a CAGR of 13.2% from 2021 to 2028. In June 2018, Celixir plc acquired Desktop Genetics to develop CRISPR-based gene editing. In August 2018, bluebird bio, Inc. and Gritstone Oncology, Inc. have collaborated to develop and commercialize cell therapy products, intended for cancer treatment. Under the agreement, Gritstone Oncology has utilized its proprietary EDGE artificial intelligence platform to analyze specific tumor types. EDGE AI platform has helped in identifying tumor-specific targets and natural T-cell receptors (TCRs) that are used as targets by bluebird bio to develop cell therapies. And further, Gritstone Oncology has utilized those identified targets to conduct development, manufacturing, and commercial processes. Thus, such innovations are expected to foster the cell therapy bioprocessing and enhance the market growth in the coming years.
Key Market Segments
In terms of technology, the bioreactors segment accounted for the largest share of the Europe cell therapy bioprocessing market in 2020. In terms of cell type, the stem cell segment accounted for the largest share of the Europe cell therapy bioprocessing market in 2020. In terms of indication, the oncology segment accounted for the largest share of the Europe cell therapy bioprocessing market in 2020. In terms of end user, the academic and research institute segment held a larger market share of the cell therapy bioprocessing market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Cell therapy bioprocessing market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Fresenius Kabi Ag., Asahi Kasei Corporation, Sartorius Ag, Merck Kgaa, Thermo Fisher Scientific Inc., Corning Incorporated, Cytiva (Ge Healthcare), Lonza, Repligen, and Catalent Inc.
Reasons to buy report
EUROPE CELL THERAPY BIOPROCESSING MARKET SEGMENTATION
By Technology
By Cell Type
By Indication
By End User
By Country
Companies Mentioned
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 3,627.3 Million |
| Market Size by 2028 | US$ 8,652.1 Million |
| CAGR (2021 - 2028) | 13.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Technology
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Cell Therapy Bioprocessing Market is valued at US$ 3,627.3 Million in 2021, it is projected to reach US$ 8,652.1 Million by 2028.
As per our report Europe Cell Therapy Bioprocessing Market, the market size is valued at US$ 3,627.3 Million in 2021, projecting it to reach US$ 8,652.1 Million by 2028. This translates to a CAGR of approximately 13.2% during the forecast period.
The Europe Cell Therapy Bioprocessing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Cell Therapy Bioprocessing Market report:
The Europe Cell Therapy Bioprocessing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Cell Therapy Bioprocessing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Cell Therapy Bioprocessing Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Cell Therapy Bioprocessing Market
